Literature DB >> 30096302

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Matthew H Bailey, Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, Michael C Wendl, Jaegil Kim, Brendan Reardon, Patrick Kwok-Shing Ng, Kang Jin Jeong, Song Cao, Zixing Wang, Jianjiong Gao, Qingsong Gao, Fang Wang, Eric Minwei Liu, Loris Mularoni, Carlota Rubio-Perez, Niranjan Nagarajan, Isidro Cortés-Ciriano, Daniel Cui Zhou, Wen-Wei Liang, Julian M Hess, Venkata D Yellapantula, David Tamborero, Abel Gonzalez-Perez, Chayaporn Suphavilai, Jia Yu Ko, Ekta Khurana, Peter J Park, Eliezer M Van Allen, Han Liang, Michael S Lawrence, Adam Godzik, Nuria Lopez-Bigas, Josh Stuart, David Wheeler, Gad Getz, Ken Chen, Alexander J Lazar, Gordon B Mills, Rachel Karchin, Li Ding.   

Abstract

Entities:  

Year:  2018        PMID: 30096302      PMCID: PMC8045146          DOI: 10.1016/j.cell.2018.07.034

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


× No keyword cloud information.
It has come to our attention that we made two errors in preparation of this manuscript. First, in the STAR Methods, under the subheading of “Hypermutators and Immune Infiltrates” within the “Quantification and Statistical Analysis” section, we inadvertently referred to Figures S7A-S7C for data corresponding to sample stratification by hypermutator status alone in the last sentence. It should have referred to Figure S6A-S6C. Second, the lists of highly frequent missense mutations for COAD (colon adenocarcinoma) and READ (rectum adenocarcinoma) displayed in Figure S7 were incorrect because when we ordered the mutations in the initial analysis, we mistakenly combined the two cancer types COAD and READ for analysis, despite the fact that they were listed as two separate cancer types in the x-axis of the figure. After re-ordering the mutations by frequency for COAD and READ independently, information on highly frequent missense mutations for each of these cancer types is different and updated now in the revised Figure S7. These errors don’t change the major conclusions of the paper and have been corrected online. We apologize for any confusion they may have caused.
Figure S7.

On-Label/Off-Label Calculations for Druggable Mutations in Cancer (original)

Figure S7.

On-Label/Off-Label Calculations for Druggable Mutations in Cancer (corrected)

  159 in total

1.  Whole exome profiling and mutational analysis of Ocular Surface Squamous Neoplasia.

Authors:  Nallely Ramos-Betancourt; Matthew G Field; Jesus H Davila-Alquisiras; Carol L Karp; Luis F Hernández-Zimbrón; Roberto García-Vázquez; Kristian A Vazquez-Romo; Gaofeng Wang; Jans Fromow-Guerra; Everardo Hernandez-Quintela; Anat Galor
Journal:  Ocul Surf       Date:  2020-07-24       Impact factor: 5.033

2.  Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.

Authors:  Joseph H McAbee; Barbara H Rath; Kristin Valdez; Dejauwne L Young; Xiaolin Wu; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2019-10-15       Impact factor: 12.701

3.  Prospective Clinical Sequencing of Adult Glioma.

Authors:  Siyuan Zheng; Kristin Alfaro-Munoz; Wei Wei; Xiaojing Wang; Fang Wang; Agda Karina Eterovic; Kenna R Mills Shaw; Funda Meric-Bernstam; Gregory N Fuller; Ken Chen; Roel G Verhaak; Gordon B Mills; W K Alfred Yung; Shiao-Pei Weathers; John F de Groot
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

4.  Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Authors:  Pedram Razavi; Jared L Johnson; Hong Shao; Neil Vasan; Hardik Shah; Alesia Antoine; Erik Ladewig; Alexander Gorelick; Ting-Yu Lin; Eneda Toska; Guotai Xu; Abiha Kazmi; Matthew T Chang; Barry S Taylor; Maura N Dickler; Komal Jhaveri; Sarat Chandarlapaty; Raul Rabadan; Ed Reznik; Melissa L Smith; Robert Sebra; Frauke Schimmoller; Timothy R Wilson; Lori S Friedman; Lewis C Cantley; Maurizio Scaltriti; José Baselga
Journal:  Science       Date:  2019-11-08       Impact factor: 47.728

5.  TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data.

Authors:  Mei-Ju May Chen; Jun Li; Yumeng Wang; Rehan Akbani; Yiling Lu; Gordon B Mills; Han Liang
Journal:  Mol Cell Proteomics       Date:  2019-06-14       Impact factor: 5.911

6.  A protein-centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes.

Authors:  Ginny X H Li; Dan Munro; Damian Fermin; Christine Vogel; Hyungwon Choi
Journal:  Hum Mutat       Date:  2020-01-23       Impact factor: 4.878

7.  The molecular genetic make-up of male breast cancer.

Authors:  Cathy B Moelans; Joep de Ligt; Petra van der Groep; Pjotr Prins; Nicolle J M Besselink; Marlous Hoogstraat; Natalie D Ter Hoeve; Miangela M Lacle; Robert Kornegoor; Carmen C van der Pol; Wendy W J de Leng; Ellis Barbé; Bert van der Vegt; John Martens; Peter Bult; Vincent T H B M Smit; Marco J Koudijs; Isaac J Nijman; Emile E Voest; Pier Selenica; Britta Weigelt; Jorge S Reis-Filho; Elsken van der Wall; Edwin Cuppen; Paul J van Diest
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

8.  Comprehensive Detection of Single Amino Acid Variants and Evaluation of Their Deleterious Potential in a PANC-1 Cell Line.

Authors:  Zhijing Tan; Jianhui Zhu; Paul M Stemmer; Liangliang Sun; Zhichang Yang; Kendall Schultz; Matthew J Gaffrey; Anthony J Cesnik; Xinpei Yi; Xiaohu Hao; Michael R Shortreed; Tujin Shi; David M Lubman
Journal:  J Proteome Res       Date:  2020-02-27       Impact factor: 4.466

9.  An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases.

Authors:  Di Chen; Zhen Ning; Huan Chen; Chang Lu; Xiaolong Liu; Tian Xia; Huan Qi; Wen Wang; Ting Ling; Xin Guo; Dinesh Singh Tekcham; Xiumei Liu; Jing Liu; Aman Wang; Qiu Yan; Ji-Wei Liu; Guang Tan; Hai-Long Piao
Journal:  Oncogene       Date:  2019-09-11       Impact factor: 9.867

10.  PDCD4 limits prooncogenic neuregulin-ErbB signaling.

Authors:  Juan Carlos Montero; Atanasio Pandiella
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.